100 related articles for article (PubMed ID: 18495790)
1. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
Attard G; Ang JE; Olmos D; de Bono JS
J Clin Pathol; 2008 Aug; 61(8):891-6. PubMed ID: 18495790
[TBL] [Abstract][Full Text] [Related]
2. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
3. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
4. [Molecular biology and prostate cancer: evolution or revolution?].
Molinié V; Beuzeboc P; Mahjoub WK;
Ann Pathol; 2008 Oct; 28(5):354-62. PubMed ID: 19068390
[TBL] [Abstract][Full Text] [Related]
5. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
Turner DP; Watson DK
Expert Rev Anticancer Ther; 2008 Jan; 8(1):33-42. PubMed ID: 18095881
[TBL] [Abstract][Full Text] [Related]
6. [Research at the Ulm University in prostate cancer].
Rinnab L; Cronauer M; Spindler D; Hautmann RE; Küfer R
Urologe A; 2007 Sep; 46(9):1071-7. PubMed ID: 17628778
[No Abstract] [Full Text] [Related]
7. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
8. [Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy].
Schmidt F; Scheble V; Mertz K; Perner S; Rubin MA
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1483-6. PubMed ID: 19572250
[TBL] [Abstract][Full Text] [Related]
9. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
[TBL] [Abstract][Full Text] [Related]
10. Evidence of recurrent gene fusions in common epithelial tumors.
Kumar-Sinha C; Tomlins SA; Chinnaiyan AM
Trends Mol Med; 2006 Nov; 12(11):529-36. PubMed ID: 17011825
[TBL] [Abstract][Full Text] [Related]
11. [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
Beuzeboc P; Soulié M; Richaud P; Salomon L; Staerman F; Peyromaure M; Mongiat-Artus P; Cornud F; Paparel P; Davin JL; Molinié V
Prog Urol; 2009 Dec; 19(11):819-24. PubMed ID: 19945666
[TBL] [Abstract][Full Text] [Related]
12. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of prostate cancer: clinical translational opportunities.
Vecchione A; Gottardo F; Gomella LG; Wildemore B; Fassan Ms; Bragantini E; Pagano F; Baffa R
J Exp Clin Cancer Res; 2007 Mar; 26(1):25-37. PubMed ID: 17550130
[TBL] [Abstract][Full Text] [Related]
14. [Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].
Perner S
Pathologe; 2010 Oct; 31 Suppl 2():121-5. PubMed ID: 20798944
[TBL] [Abstract][Full Text] [Related]
15. ETS rearrangements in prostate cancer.
Rubin MA
Asian J Androl; 2012 May; 14(3):393-9. PubMed ID: 22504874
[TBL] [Abstract][Full Text] [Related]
16. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
17. Common gene rearrangements in prostate cancer.
Rubin MA; Maher CA; Chinnaiyan AM
J Clin Oncol; 2011 Sep; 29(27):3659-68. PubMed ID: 21859993
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.
Wyatt AW; Mo F; Wang K; McConeghy B; Brahmbhatt S; Jong L; Mitchell DM; Johnston RL; Haegert A; Li E; Liew J; Yeung J; Shrestha R; Lapuk AV; McPherson A; Shukin R; Bell RH; Anderson S; Bishop J; Hurtado-Coll A; Xiao H; Chinnaiyan AM; Mehra R; Lin D; Wang Y; Fazli L; Gleave ME; Volik SV; Collins CC
Genome Biol; 2014 Aug; 15(8):426. PubMed ID: 25155515
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
20. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
